320 related articles for article (PubMed ID: 30564615)
1. Neurofilament light chain serum levels correlate with 10-year MRI outcomes in multiple sclerosis.
Chitnis T; Gonzalez C; Healy BC; Saxena S; Rosso M; Barro C; Michalak Z; Paul A; Kivisakk P; Diaz-Cruz C; Sattarnezhad N; Pierre IV; Glanz BI; Tomic D; Kropshofer H; Häring D; Leppert D; Kappos L; Bakshi R; Weiner HL; Kuhle J
Ann Clin Transl Neurol; 2018 Dec; 5(12):1478-1491. PubMed ID: 30564615
[TBL] [Abstract][Full Text] [Related]
2. Early neurofilament light and glial fibrillary acidic protein levels improve predictive models of multiple sclerosis outcomes.
Bose G; Healy BC; Saxena S; Saleh F; Paul A; Barro C; Lokhande HA; Polgar-Turcsanyi M; Anderson M; Glanz BI; Guttmann CRG; Bakshi R; Weiner HL; Chitnis T
Mult Scler Relat Disord; 2023 Jun; 74():104695. PubMed ID: 37060852
[TBL] [Abstract][Full Text] [Related]
3. Serum NfL levels in the first five years predict 10-year thalamic fraction in patients with MS.
Lokhande H; Rosso M; Tauhid S; Chu R; Healy BC; Saxena S; Barro C; Paul A; Polgar-Turcsanyi M; Anderson M; Glanz BI; Kropshofer H; Granziera C; Leppert D; Kappos L; Kuhle J; Weiner HL; Bakshi R; Chitnis T
Mult Scler J Exp Transl Clin; 2022; 8(1):20552173211069348. PubMed ID: 35035990
[TBL] [Abstract][Full Text] [Related]
4. Brain disconnectome mapping derived from white matter lesions and serum neurofilament light levels in multiple sclerosis: A longitudinal multicenter study.
Rise HH; Brune S; Chien C; Berge T; Bos SD; Andorrà M; Valdeolivas IP; Beyer MK; Sowa P; Scheel M; Brandt AU; Asseyer S; Blennow K; Pedersen ML; Zetterberg H; de Schotten MT; Cellerino M; Uccelli A; Paul F; Villoslada P; Harbo HF; Westlye LT; Høgestøl EA
Neuroimage Clin; 2022; 35():103099. PubMed ID: 35772194
[TBL] [Abstract][Full Text] [Related]
5. Neurofilament light levels are associated with long-term outcomes in multiple sclerosis.
Kuhle J; Plavina T; Barro C; Disanto G; Sangurdekar D; Singh CM; de Moor C; Engle B; Kieseier BC; Fisher E; Kappos L; Rudick RA; Goyal J
Mult Scler; 2020 Nov; 26(13):1691-1699. PubMed ID: 31680621
[TBL] [Abstract][Full Text] [Related]
6. Glial and neuroaxonal biomarkers in a multiple sclerosis (MS) cohort.
Kalatha T; Hatzifilippou E; Arnaoutoglou M; Balogiannis S; Koutsouraki E
Hell J Nucl Med; 2019; 22 Suppl 2():113-121. PubMed ID: 31802051
[TBL] [Abstract][Full Text] [Related]
7. Serum neurofilament light chain correlates with myelin and axonal magnetic resonance imaging markers in multiple sclerosis.
Yik JT; Becquart P; Gill J; Petkau J; Traboulsee A; Carruthers R; Kolind SH; Devonshire V; Sayao AL; Schabas A; Tam R; Moore GRW; Li DKB; Stukas S; Wellington C; Quandt JA; Vavasour IM; Laule C
Mult Scler Relat Disord; 2022 Jan; 57():103366. PubMed ID: 35158472
[TBL] [Abstract][Full Text] [Related]
8. Brain MRI Predicts Worsening Multiple Sclerosis Disability over 5 Years in the SUMMIT Study.
Bakshi R; Healy BC; Dupuy SL; Kirkish G; Khalid F; Gundel T; Asteggiano C; Yousuf F; Alexander A; Hauser SL; Weiner HL; Henry RG;
J Neuroimaging; 2020 Mar; 30(2):212-218. PubMed ID: 31994814
[TBL] [Abstract][Full Text] [Related]
9. Whole-brain atrophy assessed by proportional- versus registration-based pipelines from 3T MRI in multiple sclerosis.
Hemond CC; Chu R; Tummala S; Tauhid S; Healy BC; Bakshi R
Brain Behav; 2018 Aug; 8(8):e01068. PubMed ID: 30019857
[TBL] [Abstract][Full Text] [Related]
10. Predicting clinical progression in multiple sclerosis with the magnetic resonance disease severity scale.
Bakshi R; Neema M; Healy BC; Liptak Z; Betensky RA; Buckle GJ; Gauthier SA; Stankiewicz J; Meier D; Egorova S; Arora A; Guss ZD; Glanz B; Khoury SJ; Guttmann CR; Weiner HL
Arch Neurol; 2008 Nov; 65(11):1449-53. PubMed ID: 19001162
[TBL] [Abstract][Full Text] [Related]
11. Ultrasensitive immunoassay allows measurement of serum neurofilament heavy in multiple sclerosis.
Verberk IMW; Koel-Simmelink M; Twaalfhoven H; Vrenken H; Korth C; Killestein J; Teunissen CE; Bridel C
Mult Scler Relat Disord; 2021 May; 50():102840. PubMed ID: 33626430
[TBL] [Abstract][Full Text] [Related]
12. Neurofilament levels, disease activity and brain volume during follow-up in multiple sclerosis.
Håkansson I; Tisell A; Cassel P; Blennow K; Zetterberg H; Lundberg P; Dahle C; Vrethem M; Ernerudh J
J Neuroinflammation; 2018 Jul; 15(1):209. PubMed ID: 30021640
[TBL] [Abstract][Full Text] [Related]
13. High serum neurofilament light chain normalizes after hematopoietic stem cell transplantation for MS.
Thebault S; R Tessier D; Lee H; Bowman M; Bar-Or A; Arnold DL; L Atkins H; Tabard-Cossa V; Freedman MS
Neurol Neuroimmunol Neuroinflamm; 2019 Sep; 6(5):e598. PubMed ID: 31516913
[TBL] [Abstract][Full Text] [Related]
14. CSF neurofilament light chain predicts 10-year clinical and radiologic worsening in multiple sclerosis.
Bhan A; Jacobsen C; Dalen I; Bergsland N; Zivadinov R; Alves G; Myhr KM; Farbu E
Mult Scler J Exp Transl Clin; 2021 Oct; 7(4):20552173211060337. PubMed ID: 34900328
[TBL] [Abstract][Full Text] [Related]
15. Technology-enabled comprehensive characterization of multiple sclerosis in clinical practice.
Baldassari LE; Nakamura K; Moss BP; Macaron G; Li H; Weber M; Jones SE; Rao SM; Miller D; Conway DS; Bermel RA; Cohen JA; Ontaneda D; McGinley MP
Mult Scler Relat Disord; 2020 Feb; 38():101525. PubMed ID: 31759186
[TBL] [Abstract][Full Text] [Related]
16. Serum neurofilament light chain in early relapsing remitting MS is increased and correlates with CSF levels and with MRI measures of disease severity.
Kuhle J; Barro C; Disanto G; Mathias A; Soneson C; Bonnier G; Yaldizli Ö; Regeniter A; Derfuss T; Canales M; Schluep M; Du Pasquier R; Krueger G; Granziera C
Mult Scler; 2016 Oct; 22(12):1550-1559. PubMed ID: 26754800
[TBL] [Abstract][Full Text] [Related]
17. Neurofilament light chain and MRI volume parameters as markers of neurodegeneration in multiple sclerosis.
Filippi P; Vestenická V; Siarnik P; Sivakova M; Čopíková-Cudráková D; Belan V; Hanes J; Novák M; Kollar B; Turcani P
Neuro Endocrinol Lett; 2020 Apr; 41(1):17-26. PubMed ID: 32338853
[TBL] [Abstract][Full Text] [Related]
18. Using multiple imputation to efficiently correct cerebral MRI whole brain lesion and atrophy data in patients with multiple sclerosis.
Chua AS; Egorova S; Anderson MC; Polgar-Turcsanyi M; Chitnis T; Weiner HL; Guttmann CR; Bakshi R; Healy BC
Neuroimage; 2015 Oct; 119():81-8. PubMed ID: 26093330
[TBL] [Abstract][Full Text] [Related]
19. The effect of alcohol and red wine consumption on clinical and MRI outcomes in multiple sclerosis.
Diaz-Cruz C; Chua AS; Malik MT; Kaplan T; Glanz BI; Egorova S; Guttmann CRG; Bakshi R; Weiner HL; Healy BC; Chitnis T
Mult Scler Relat Disord; 2017 Oct; 17():47-53. PubMed ID: 29055473
[TBL] [Abstract][Full Text] [Related]
20. Association Between Serum MicroRNAs and Magnetic Resonance Imaging Measures of Multiple Sclerosis Severity.
Regev K; Healy BC; Khalid F; Paul A; Chu R; Tauhid S; Tummala S; Diaz-Cruz C; Raheja R; Mazzola MA; von Glehn F; Kivisakk P; Dupuy SL; Kim G; Chitnis T; Weiner HL; Gandhi R; Bakshi R
JAMA Neurol; 2017 Mar; 74(3):275-285. PubMed ID: 28114622
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
